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Background
We conducted a post-hoc analysis of two short-ragweed
sublingual immunotherapy tablet (SLIT-T) trials to
investigate whether the subjects with allergic rhinitis
with/without conjunctivitis (AR/C) and comorbid asthma
reported different efficacy or safety events than those
with AR/C and no asthma.
Methods
Data from two trials evaluating the short-ragweed SLIT-T
MK-3641 (Ambrosia artemisiifolia; Merck/ALK-Abelló)
were pooled. Subjects with ragweed-pollen–induced AR/C
were randomized to once-daily MK-3641 (6 or 12 Amb a
1-U doses) or placebo for approximately 52 weeks. Sub-
jects with AR/C and stable asthma not requiring medium-
or high-dose inhaled corticosteroids and ≥70% predicted
FEV1 were eligible. Efficacy and safety outcomes were
assessed in subjects with AR/C with/without reported
asthma. Efficacy measurements included AR/C total com-
bined score (TCS; combined symptom+medication
scores); safety was assessed by reported adverse events
(AEs).
Results
Among subjects with AR/C and asthma receiving MK-
3641 6 or 12 Amb a 1-U, TCS was reduced by 17%
(−1.27; 95% CI: −3.48, 0.93; n=56) and 22% (−1.68; 95%
CI: −3.69, 0.33; n=64), respectively, versus placebo
(mean TCS=7.65; n=64) over the 15-day peak season.
Among subjects without asthma receiving MK-3641 6
or 12 Amb a 1-U, TCS was reduced by 21% (−1.83; 95%
CI: −2.84, −0.82; n=261) and 27% (−2.34; 95% CI: −3.33,
−1.35; n=247), respectively, versus placebo (mean
TCS=8.73; n=269). At least one treatment-related AE
was experienced by 33%, 63%, and 65% of placebo and
MK-3641 6 and 12 Amb a 1-U subjects with asthma,
respectively, versus 24%, 54%, and 60% of subjects with-
out asthma. No treatment-related serious or life-threa-
tening AEs or hypersensitivity or systemic reactions
were observed.
Conclusions
The overall number of subjects with asthma was low
and the data must be interpreted with caution. However,
the SLIT-T treatment MK-3641 appeared to demon-
strate similar efficacy and safety results in subjects with
ragweed AR/C with or without asthma.
Trial registration
ClinicalTrials.gov Identifiers: NCT00783198; NCT00770315.
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